New drug KUP-101A enters first human tests for advanced skin cancers
NCT ID NCT07600476
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measure how the drug moves through the body and get early signs of whether it can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA OF SKIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fachklinik Hornheide
RECRUITINGMünster, North Rhine-Westphalia, 48157, Germany
-
Universitätsklinikum Würzburg
RECRUITINGWürzburg, Bavaria, 97080, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single tracer light up cancer's first stop? a trial puts a hybrid dye-and-radioactive marker to the test.
- Could a Two-Drug combo reawaken the immune system against resistant cancers?
- Immunotherapy may treat skin cancer in kidney transplant patients without rejection
- New drug cocktail targets rare, aggressive melanoma
- AI-Powered microscope could diagnose skin cancer in minutes
- Blood clot marker may predict immunotherapy success in advanced skin cancer